SecSonar.com

Caris Life Sciences, Inc. (CAI)

Caris Life Sciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Caris Life Sciences, Inc. (CAI) is a Biotechnology company based in US with a market capitalization of $4.7B. Revenue grew 97.0% year-over-year and the company generated $66.9M in free cash flow. This page tracks CAI's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 1.77K employees · IPO Jun 18, 2025

Valuation

Valuation & price

$14.55 · as of May 17, 2026 · -63.0% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

8.19

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$38.48$26.79$15.10Jul 25Dec 25Jul 26Jul 7, 25$26.53Jul 9, 25$27.24Jul 11, 25$26.51Jul 15, 25$28.91Jul 17, 25$31.28Jul 21, 25$28.29Jul 23, 25$30.03Jul 25, 25$29.54Jul 29, 25$27.52Jul 31, 25$28.08Aug 4, 25$29.49Aug 6, 25$28.95Aug 11, 25$30.21Aug 13, 25$34.28Aug 15, 25$36.50Aug 19, 25$36.93Aug 21, 25$38.12Aug 25, 25$38.48Aug 27, 25$38.22Aug 29, 25$38.39Sep 3, 25$36.80Sep 5, 25$34.85Sep 9, 25$33.95Sep 11, 25$34.21Sep 16, 25$33.66Sep 18, 25$33.43Sep 22, 25$32.94Sep 24, 25$30.44Sep 26, 25$29.19Sep 30, 25$30.25Oct 2, 25$29.71Oct 6, 25$32.81Oct 8, 25$32.95Oct 10, 25$30.48Oct 14, 25$30.36Oct 16, 25$31.95Oct 21, 25$31.53Oct 23, 25$31.66Oct 27, 25$30.25Oct 29, 25$29.43Oct 31, 25$30.08Nov 4, 25$31.18Nov 6, 25$24.61Nov 10, 25$24.80Nov 12, 25$24.77Nov 14, 25$23.85Nov 18, 25$23.76Nov 20, 25$24.03Nov 25, 25$25.58Nov 28, 25$25.53Dec 2, 25$26.11Dec 4, 25$28.32Dec 8, 25$28.36Dec 10, 25$27.10Dec 12, 25$26.76Dec 16, 25$27.60Dec 18, 25$27.86Dec 22, 25$28.46Dec 24, 25$28.24Dec 29, 25$27.95Jan 2, 26$26.98Jan 6, 26$28.38Jan 8, 26$28.25Jan 12, 26$25.60Jan 14, 26$26.42Jan 16, 26$26.78Jan 21, 26$25.48Jan 23, 26$25.00Jan 27, 26$26.01Jan 29, 26$25.20Feb 2, 26$23.32Feb 4, 26$21.84Feb 9, 26$22.31Feb 11, 26$21.50Feb 13, 26$20.62Feb 18, 26$21.05Feb 20, 26$19.53Feb 24, 26$18.20Feb 26, 26$19.24Mar 2, 26$20.66Mar 4, 26$19.86Mar 6, 26$18.59Mar 10, 26$18.54Mar 12, 26$17.69Mar 17, 26$18.54Mar 19, 26$18.81Mar 23, 26$19.26Mar 25, 26$18.56Mar 27, 26$16.95Mar 31, 26$17.88Apr 2, 26$19.29Apr 7, 26$18.75Apr 9, 26$19.20Apr 13, 26$19.13Apr 15, 26$20.95Apr 17, 26$21.15Apr 22, 26$20.50Apr 24, 26$20.20Apr 28, 26$18.44Apr 30, 26$19.00May 4, 26$18.69May 6, 26$19.13May 8, 26$16.15May 12, 26$16.76May 14, 26$15.25May 18, 26$15.10May 20, 26$15.70May 22, 26$15.55May 28, 26$16.67Jun 1, 26$16.45Jun 3, 26$15.48Jun 5, 26$16.49Jun 9, 26$16.96Jun 11, 26$18.00Jun 15, 26$18.18Jun 17, 26$17.86Jun 22, 26$17.31Jun 24, 26$18.15Jun 26, 26$18.50Jul 2, 26$18.30
$14.5552-week range$39.30
Loading valuation history…

Fundamentals

Key fundamentals

$4.7B

Market cap

97.0%

Revenue growth (YoY)

66.4%

Gross margin

$66.9M

Free cash flow (USD)

-$421.1M

Net debt

Net cash position

556.6%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2015 → 2025

FY 2015$249.7MFY 2016$294.4MFY 2017$348.4MFY 2018$432.1MFY 2019$416.5MFY 2020$294.0MFY 2022$258.5MFY 2023$306.1MFY 2024$412.3MFY 2025$812.0M
$249.7M$812M

Free cash flow by year

2015 → 2025

FY 2015$-242.0MFY 2016$-122.0MFY 2017$-347.0MFY 2018$-633.1MFY 2019$-65.1MFY 2020$57.6MFY 2022$-328.0MFY 2023$-298.4MFY 2024$-253.6MFY 2025$66.9M
-$242M$66.9M

Gross margin by year

2020 → 2025

FY 202062.6%FY 202231.0%FY 202329.2%FY 202443.4%FY 202566.4%
62.6%66.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 5, 2026Filing
  • Insider buyInsider Buy $501KVacirca Jeff L · Director · $501.4KMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 8, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • 8-K eventDebt RefinancingApr 2, 2026Filing

Questions

Frequently asked questions

What is Caris Life Sciences, Inc.'s market cap?

Caris Life Sciences, Inc. (CAI) has a market capitalization of $4.7B.

What is CAI's P/E ratio?

A meaningful P/E ratio is not available for CAI — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CAI's price-to-book (P/B) ratio?

CAI trades at 8.19 times book value per share.

Are insiders buying CAI stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at Caris Life Sciences, Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

LGND

Ligand Pharmaceuticals Incorporated

$4.7B

LEGN

Legend Biotech Corporation

$5B

TVTX

Travere Therapeutics, Inc.

$4.4B

SYRE

Spyre Therapeutics, Inc.

$4.4B

MIRM

Mirum Pharmaceuticals, Inc.

$5.1B

XENE

Xenon Pharmaceuticals Inc.

$4.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.